Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"ImmunoBrain Checkpoint","sponsor":"NIA","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer\u2019s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ImmunoBrain Checkpoint"},{"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"}]

SciSparc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

Details:

The trial's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 (cannabidiol) in children and adolescents with ASD in a designed 20-week, randomized, double-blind, placebo controlled with a cross-over clinical trial of 60 children.

Lead Product(s): Cannabidiol,Cannamide

Therapeutic Area: Neurology Product Name: SCI-210

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 08, 2022

ASK
US

Upload
your Pipeline Activity

ImmunoBrain Checkpoint

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002

Details:

The grant will be used to support the first-in-human clinical study of IBC-Ab002, a proprietary anti-PD-L1 antibody developed and engineered with differentiating characteristics tailored for the treatment of Alzheimer’s disease.

Lead Product(s): IBC-Ab002

Therapeutic Area: Neurology Product Name: IBC-Ab002

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: NIA

Deal Size: $5.0 million Upfront Cash: Undisclosed

Deal Type: Funding August 27, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY